Tumour Registry Breast Cancer

Completed

• Conditions: Breast Cancer

• Registration Number: NCT01351584
• Lead Sponsor: iOMEDICO AG

Brief Summary

The registry aims to collect and analyse information on the antineoplastic treatment of breast cancer in daily routine practice of office-based and clinic-based medical oncologists in Germany.

Detailed Description

The TMK is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of breast cancer in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

The impact of nutrition (MaNut) and physical activity (MaNut) on the course of the adjuvant disease will be examined, as well as long-term effects of adjuvant treatment (MaTox) and the multiple patient-reported outcomes (MaLife).

Study Timeline

• Study Start: 2007-02
• Study First Submitted: 2011-05-09
• Study First Submitted QC: 2011-05-09
• Study First Posted: 2011-05-11
• Primary Completion: 2021-12
• Study Completion: 2021-12
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-23
• Last Update Posted: 2022-02-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 4500

Inclusion Criteria

• Breast cancer
• 18 years and older
• Antineoplastic or antihormonal treatment

Read More

Exclusion Criteria

• No breast cancer
• Below 18 years
• No antineoplastic or antihormonal treatment

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Course of Antineoplastic Treatment	5 years